Spanish Biotech Platform
Plataforma de Mercados Biotecnológicos
Centro de Cirugía de Mínima Invasión Jesús Usón
Centro de Cirugía de Mínima Invasión Jesús Usón
 
Type
Technology center
Public entity
Contact
Javier García Casado.
Phone: 0 0
Mobile Phone: 0 0
Fax: 0 0

http://www.ccmijesususon.com/
Activity
The Jesús Usón Minimally Invasive Surgery Centre, CCMIJU, is a multidisciplinary institution dedicated to excellence in research and training in minimally invasive surgical techniques (Bioengineering and Health Technologies, Laparoscopy, Endoscopy, Microsurgery, Endoluminal Therapy and Diagnosis, Anesthesiology, Pharmacy and Cellular Therapy). Thanks to the available facilities and equipment, it is possible to develop less invasive surgical treatments by applying combined techniques and multidisciplinary equipment for treatment approach, thus benefiting the patient and providing higher precision to the surgeon. Similarly, the Centre is committed to technological development and innovation in health care, and for its advancement it works closely with companies from all over the world. Besides, since the CCMIJU is free from medical assistance, it joins all its efforts and resources into research. In short, this activity will have an impact on higher clinical quality for human patients and on the scientific and technical development within medical/surgical areas.
The latest generation equipments and facilities are available at the Centre, allowing for the highest possible level of research and training for medicine and surgery professionals worldwide and positioning it as a global leader in health applied technology.
The Centre has been awarded the following accreditations, among other:
- Quality assurance certified by AENOR (ER-0430/2002) according to the UNE-EN-ISO 9001:08 standards for “The design of applied research projects and in the theoretical and practical training in minimally invasive surgical techniques”.
- GLP Compliance Certificate (No.: BPLI 11.04/001 MSC)
This certification confirms that the CCMIJU is able to carry out studies of In Vivo Toxicity, Tolerance and Farmacodynamics of medicinal products, in both human and veterinary medicine.
The CCMJU has launched a new line of research for developing new therapies that combine the use of adult stem cells with minimally invasive surgery techniques. For this research, the Center has set up a laboratory fully equipped for the isolation, characterization and infusion of adult stem cells.
The CCMIJU is currently focused on the creation and validation of suitable animal models to assess the applicability, effectiveness and benefit of pluripotent cell implantation in the treatment of myocardial ischemia and other diseases. Finally, the Stem Cell Therapy Unit promotes the participation of CCMIJU in preclinical trials and aims to become a platform for translational research to enable accurate translation from preclinical research to clinical practice.
Permalink: http://www.mercadosbiotecnologicos.com/?eid=134&etid=3&lan=en

Search